The demand for an improvement of the biocompatibility and durability of vascular and valvular implants requires translational animal models to study the in vivo fate of cardiovascular grafts. In the present article, a review on the development and application of a microsurgical rat model of infrarenal implantation of aortic grafts and aortic valved conduits is provided. By refinement of surgical techniques and inclusion of hemodynamic considerations, a functional model has been created, which provides a modular platform for the in vivo assessment of biological and tissue-engineered grafts. Through optional addition of procalcific diets, disease-inducing agents, and genetic modifications, complex multimorbidity scenarios mimicking the clinical reality in cardiovascular patients can be simulated. Applying this model, crucial aspects of the biocompatibility, biofunctionality and degeneration of vascular and valvular implants in dependency on graft preparation, and modification as well as systemic antidegenerative treatment of the recipient have been and will be addressed.
Get full access to this article
View all access options for this article.
References
1.
AkhyariP., MinolP., AssmannA., BarthM., KamiyaH., and LichtenbergA. [Tissue engineering of heart valves]. Chirurg, 82, 311, 2011.
2.
Simon-YarzaT., BatailleI., and LetourneurD.Cardiovascular bio-engineering: current state of the art. J Cardiovasc Transl Res, 10, 180, 2017.
3.
BenrashidE., McCoyC.C., YoungwirthL.M., KimJ., MansonR.J., OttoJ.C., and LawsonJ.H.Tissue engineered vascular grafts: origins, development, and current strategies for clinical application. Methods, 99, 13, 2016.
4.
Pashneh-TalaS., MacNeilS., and ClaeyssensF.The tissue-engineered vascular graft-past, present, and future. Tissue Eng Part B Rev, 22, 68, 2016.
5.
JaspanV.N., and HinesG.L.The current status of tissue-engineered vascular grafts. Cardiol Rev, 23, 236, 2015.
6.
HessF., JerusalemC., BraunB., and GrandeP.Three years experience with experimental implantation of fibrous polyurethane microvascular prostheses in the rat aorta. Microsurgery, 6, 155, 1985.
7.
HeimC., EcklS., PreidlR., Ramsperger-GleixnerM., KochN., GoldmannK., SpriewaldB.M., WeyandM., and EnsmingerS.M.Delayed therapy with clopidogrel and everolimus prevents progression of transplant arteriosclerosis and impairs humoral alloimmunity in murine aortic allografts. Eur J Cardiothorac Surg, 47, 180, 2015.
8.
AubinH., Mas-MorunoC., IijimaM., SchutterleN., SteinbrinkM., AssmannA., GilF.J., LichtenbergA., PeguerolesM., and AkhyariP.Customized interface biofunctionalization of decellularized extracellular matrix: toward enhanced endothelialization. Tissue Eng Part C Methods, 22, 496, 2016.
9.
AssmannA., DelfsC., MunakataH., SchifferF., HorstkotterK., HuynhK., BarthM., StoldtV.R., KamiyaH., BoekenU., LichtenbergA., and AkhyariP.Acceleration of autologous in vivo recellularization of decellularized aortic conduits by fibronectin surface coating. Biomaterials, 34, 6015, 2013.
10.
AssmannA., StrussM., SchifferF., HeidelbergF., MunakataH., TimchenkoE.V., TimchenkoP.E., KaufmannT., HuynhK., SugimuraY., LeidlQ., PintoA., StoldtV.R., LichtenbergA., and AkhyariP.Improvement of the in vivo cellular repopulation of decellularized cardiovascular tissues by a detergent-free, non-proteolytic, actin-disassembling regimen. J Tissue Eng Regen Med, 2017 [Epub ahead of print]; DOI: 10.1002/term.2271.
11.
AssmannA., ZwirnmannK., HeidelbergF., SchifferF., HorstkotterK., MunakataH., GremseF., BarthM., LichtenbergA., and AkhyariP.The degeneration of biological cardiovascular prostheses under pro-calcific metabolic conditions in a small animal model. Biomaterials, 35, 7416, 2014.
12.
MunakataH., AssmannA., Poudel-BochmannB., HorstkotterK., KamiyaH., OkitaY., LichtenbergA., and AkhyariP.Aortic conduit valve model with controlled moderate aortic regurgitation in rats: a technical modification to improve short- and long-term outcome and to increase the functional results. Circ J, 77, 2295, 2013.
13.
AssmannA., AkhyariP., DelfsC., FlogelU., JacobyC., KamiyaH., and LichtenbergA.Development of a growing rat model for the in vivo assessment of engineered aortic conduits. J Surg Res, 176, 367, 2012.
14.
AssmannA., HorstkotterK., MunakataH., SchifferF., DelfsC., ZwirnmannK., BarthM., AkhyariP., and LichtenbergA.Simvastatin does not diminish the in vivo degeneration of decellularized aortic conduits. J Cardiovasc Pharmacol, 64, 332, 2014.
15.
BellonJ.M., BujanJ., ContrerasL.A., and JuradoF.Use of nonporous polytetrafluoroethylene prosthesis in combination with polypropylene prosthetic abdominal wall implants in prevention of peritoneal adhesions. J Biomed Mater Res, 38, 197, 1997.
16.
DhahriM., Rodriguez-RuizV., Aid-LaunaisR., OllivierV., Pavon-DjavidG., JourneC., LouedecL., ChaubetF., LetourneurD., MaaroufiR.M., and Meddahi-PelleA.In vitro and in vivo hemocompatibility evaluation of a new dermatan sulfate-modified PET patch for vascular repair surgery. J Biomed Mater Res B Appl Biomater, 105, 2001, 2017.
17.
LaiP.H., ChangY., LiangH.C., ChenS.C., WeiH.J., and SungH.W.Peritoneal regeneration induced by an acellular bovine pericardial patch in the repair of abdominal wall defects. J Surg Res, 127, 85, 2005.
18.
YehH.S., KellerJ.T., BrackettK.A., FrankE., and TewJ.M.Jr. Human umbilical artery for microvascular grafting. Experimental study in the rat. J Neurosurg, 61, 737, 1984.
19.
YankahA.C., WottgeH.U., and Muller-RuchholtzW.Prognostic importance of viability and a study of a second set allograft valve: an experimental study. J Card Surg, 3, 263, 1988.
20.
ZhouZ.Y., GolshaniS.D., WelliszT., RossoR.F., NimniM.E., and ReinischJ.F.A new model for heterotopic aortic valve transplantation. Transplantation, 64, 228, 1997.
21.
OeiF.B., WeltersM.J., BonthuisF., VaessenL.M., MarquetR.L., ZondervanP.E., WeimarW., and BogersA.J.A size-matching heterotopic aortic valve implantation model in the rat. J Surg Res, 87, 239, 1999.
22.
KallenbachK., SorrentinoS., MertschingH., KostinS., PethigK., HaverichA., and CebotariS.A novel small-animal model for accelerated investigation of tissue-engineered aortic valve conduits. Tissue Eng Part C Methods, 16, 41, 2010.
23.
LegareJ.F., NantonM.A., BryanP., LeeT.D., and RossD.B.Aortic valve graft implantation in rats: a new functional model. J Thorac Cardiovasc Surg, 120, 679, 2000.
24.
GraussR.W., HazekampM.G., van VlietS., Gittenberger-de GrootA.C., and DeRuiterM.C.Decellularization of rat aortic valve allografts reduces leaflet destruction and extracellular matrix remodeling. J Thorac Cardiovasc Surg, 126, 2003, 2003.
25.
RossD.N.Evolution of the homograft valve. Ann Thorac Surg, 59, 565, 1995.
GreenM.K., WalshM.D., DareA., HoganP.G., ZhaoX.M., FrazerI.H., BansalA.S., and O'BrienM.F.Histologic and immunohistochemical responses after aortic valve allografts in the rat. Ann Thorac Surg, 66, S216, 1998.
28.
LegareJ.F., LeeT.D., CreaserK., and RossD.B.T lymphocytes mediate leaflet destruction and allograft aortic valve failure in rats. Ann Thorac Surg, 70, 1238, 2000.
29.
SimonP., KasimirM.T., SeebacherG., WeigelG., UllrichR., Salzer-MuharU., RiederE., and WolnerE.Early failure of the tissue engineered porcine heart valve SYNERGRAFT in pediatric patients. Eur J Cardiothorac Surg, 23, 1002, 2003.
30.
RufferA., PurbojoA., CichaI., GlocklerM., PotapovS., DittrichS., and CesnjevarR.A.Early failure of xenogenous de-cellularised pulmonary valve conduits—a word of caution!. Eur J Cardiothorac Surg, 38, 78, 2010.
31.
MeyerS.R., NagendranJ., DesaiL.S., RayatG.R., ChurchillT.A., AndersonC.C., RajotteR.V., LakeyJ.R., and RossD.B.Decellularization reduces the immune response to aortic valve allografts in the rat. J Thorac Cardiovasc Surg, 130, 469, 2005.
HopkinsR.A., JonesA.L., WolfinbargerL., MooreM.A., BertA.A., and LoflandG.K.Decellularization reduces calcification while improving both durability and 1-year functional results of pulmonary homograft valves in juvenile sheep. J Thorac Cardiovasc Surg, 137, 907, 2009.
34.
ChenA.F., ChenD.D., DaiberA., FaraciF.M., LiH., RemboldC.M., and LaherI.Free radical biology of the cardiovascular system. Clin Sci (Lond), 123, 73, 2012.
35.
DamascenoD.C., NettoA.O., IessiI.L., GallegoF.Q., CorvinoS.B., DallaquaB., SinzatoY.K., BuenoA., CalderonI.M., and RudgeM.V.Streptozotocin-induced diabetes models: pathophysiological mechanisms and fetal outcomes. Biomed Res Int, 2014, 819065, 2014.
36.
MasielloP., BrocaC., GrossR., RoyeM., ManteghettiM., Hillaire-BuysD., NovelliM., and RibesG.Experimental NIDDM: development of a new model in adult rats administered streptozotocin and nicotinamide. Diabetes, 47, 224, 1998.
37.
SzkudelskiT.Streptozotocin-nicotinamide-induced diabetes in the rat. Characteristics of the experimental model. Exp Biol Med (Maywood), 237, 481, 2012.
38.
GhasemiA., KhalifiS., and JediS.Streptozotocin-nicotinamide-induced rat model of type 2 diabetes (review). Acta Physiol Hung, 101, 408, 2014.
39.
van KoppenA., VerhaarM.C., BongartzL.G., and JolesJ.A. 5/6th nephrectomy in combination with high salt diet and nitric oxide synthase inhibition to induce chronic kidney disease in the Lewis rat. J Vis Exp. e50398, 2013.
40.
BongartzL.G., BraamB., VerhaarM.C., CramerM.J., GoldschmedingR., GaillardC.A., DoevendansP.A., and JolesJ.A.Transient nitric oxide reduction induces permanent cardiac systolic dysfunction and worsens kidney damage in rats with chronic kidney disease. Am J Physiol Regul Integr Comp Physiol, 298, R815, 2010.
41.
Al HaririM., ZibaraK., FarhatW., HashemY., SoudaniN., Al IbrahimF., HamadeE., ZeidanA., HusariA., and KobeissyF.Cigarette smoking-induced cardiac hypertrophy, vascular inflammation and injury are attenuated by antioxidant supplementation in an animal model. Front Pharmacol, 7, 397, 2016.
42.
MillerJ.D., ChuY., BrooksR.M., RichenbacherW.E., Pena-SilvaR., and HeistadD.D.Dysregulation of antioxidant mechanisms contributes to increased oxidative stress in calcific aortic valvular stenosis in humans. J Am Coll Cardiol, 52, 843, 2008.
43.
LegareJ.F., LeeT.D., and RossD.B.Cryopreservation of rat aortic valves results in increased structural failure. Circulation, 102, III75, 2000.
44.
BarakiH., TudoracheI., BraunM., HofflerK., GorlerA., LichtenbergA., BaraC., CalistruA., BrandesG., Hewicker-TrautweinM., HilfikerA., HaverichA., and CebotariS.Orthotopic replacement of the aortic valve with decellularized allograft in a sheep model. Biomaterials, 30, 6240, 2009.
45.
MartinN.D., SchanerP.J., TulenkoT.N., ShapiroI.M., DimatteoC.A., WilliamsT.K., HagerE.S., and DiMuzioP.J.In vivo behavior of decellularized vein allograft. J Surg Res, 129, 17, 2005.
46.
Schenke-LaylandK., XieJ., Heydarkhan-HagvallS., Hamm-AlvarezS.F., StockU.A., BrockbankK.G., and MacLellanW.R.Optimized preservation of extracellular matrix in cardiac tissues: implications for long-term graft durability. Ann Thorac Surg, 83, 1641, 2007.
47.
TudoracheI., CebotariS., SturzG., KirschL., HurschlerC., HilfikerA., HaverichA., and LichtenbergA.Tissue engineering of heart valves: biomechanical and morphological properties of decellularized heart valves. J Heart Valve Dis, 16, 567, 2007.
48.
FaulkD.M., CarruthersC.A., WarnerH.J., KramerC.R., ReingJ.E., ZhangL., D'AmoreA., and BadylakS.F.The effect of detergents on the basement membrane complex of a biologic scaffold material. Acta Biomater, 10, 183, 2014.
49.
FishmanJ.M., LowdellM.W., UrbaniL., AnsariT., BurnsA.J., TurmaineM., NorthJ., SibbonsP., SeifalianA.M., WoodK.J., BirchallM.A., and De CoppiP.Immunomodulatory effect of a decellularized skeletal muscle scaffold in a discordant xenotransplantation model. Proc Natl Acad Sci U S A, 110, 14360, 2013.
50.
BoerU., LohrenzA., KlingenbergM., PichA., HaverichA., and WilhelmiM.The effect of detergent-based decellularization procedures on cellular proteins and immunogenicity in equine carotid artery grafts. Biomaterials, 32, 9730, 2011.
51.
GilliesA.R., SmithL.R., LieberR.L., and VargheseS.Method for decellularizing skeletal muscle without detergents or proteolytic enzymes. Tissue Eng Part C Methods, 17, 383, 2011.
52.
FlamengW., De VisscherG., MesureL., HermansH., JashariR., and MeurisB.Coating with fibronectin and stromal cell-derived factor-1alpha of decellularized homografts used for right ventricular outflow tract reconstruction eliminates immune response-related degeneration. J Thorac Cardiovasc Surg, 147, 1398, 2014.
53.
AkhyariP., KamiyaH., GwanmesiaP., AubinH., TschierschkeR., HoffmannS., KarckM., and LichtenbergA.In vivo functional performance and structural maturation of decellularised allogenic aortic valves in the subcoronary position. Eur J Cardiothorac Surg, 38, 539, 2010.
54.
da CostaF.D., CostaA.C., PrestesR., DomanskiA.C., BalbiE.M., FerreiraA.D., and LopesS.V.The early and midterm function of decellularized aortic valve allografts. Ann Thorac Surg, 90, 1854, 2010.
55.
CebotariS., TudoracheI., CiubotaruA., BoethigD., SarikouchS., GoerlerA., LichtenbergA., CheptanaruE., BarnaciucS., CazacuA., MaligaO., RepinO., ManiucL., BreymannT., and HaverichA.Use of fresh decellularized allografts for pulmonary valve replacement may reduce the reoperation rate in children and young adults: early report. Circulation, 124, S115, 2011.
56.
PennelT., ZillaP., and BezuidenhoutD.Differentiating transmural from transanastomotic prosthetic graft endothelialization through an isolation loop-graft model. J Vasc Surg, 58, 1053, 2013.
57.
AsaharaT., MuroharaT., SullivanA., SilverM., van der ZeeR., LiT., WitzenbichlerB., SchattemanG., and IsnerJ.M.Isolation of putative progenitor endothelial cells for angiogenesis. Science, 275, 964, 1997.
58.
RehmanJ., LiJ., OrschellC.M., and MarchK.L.Peripheral blood “endothelial progenitor cells” are derived from monocyte/macrophages and secrete angiogenic growth factors. Circulation, 107, 1164, 2003.
59.
FadiniG.P., and AvogaroA.Potential manipulation of endothelial progenitor cells in diabetes and its complications. Diabetes Obes Metab, 12, 570, 2010.
60.
CebotariS., WallesT., SorrentinoS., HaverichA., and MertschingH.Guided tissue regeneration of vascular grafts in the peritoneal cavity. Circ Res, 90, e71, 2002.
61.
MuylaertD.E., FledderusJ.O., BoutenC.V., DankersP.Y., and VerhaarM.C.Combining tissue repair and tissue engineering; bioactivating implantable cell-free vascular scaffolds. Heart, 100, 1825, 2014.
62.
ValenickL.V., HsiaH.C., and SchwarzbauerJ.E.Fibronectin fragmentation promotes alpha4beta1 integrin-mediated contraction of a fibrin-fibronectin provisional matrix. Exp Cell Res, 309, 48, 2005.
63.
IijimaM., AubinH., SteinbrinkM., SchifferF., AssmannA., WeiselR.D., MatsuiY., LiR.K., LichtenbergA., and AkhyariP.Bioactive coating of decellularized vascular grafts with a temperature-sensitive VEGF-conjugated hydrogel accelerates autologous endothelialization in vivo. J Tissue Eng Regen Med, 2016 [Epub ahead of print]; DOI: 10.1002/term.2321.
64.
TsaiT.N., KirtonJ.P., CampagnoloP., ZhangL., XiaoQ., ZhangZ., WangW., HuY., and XuQ.Contribution of stem cells to neointimal formation of decellularized vessel grafts in a novel mouse model. Am J Pathol, 181, 362, 2012.
65.
GoelH.L., and MercurioA.M.VEGF targets the tumour cell. Nat Rev Cancer, 13, 871, 2013.
66.
ZhouJ., YeX., WangZ., LiuJ., ZhangB., QiuJ., SunY., LiH., and ZhaoQ.Development of decellularized aortic valvular conduit coated by heparin-SDF-1alpha multilayer. Ann Thorac Surg, 99, 612, 2015.
67.
ZhouM., LiuZ., LiK., QiaoW., JiangX., RanF., QiaoT., and LiuC.Beneficial effects of granulocyte-colony stimulating factor on small-diameter heparin immobilized decellularized vascular graft. J Biomed Mater Res A, 95, 600, 2010.
68.
De VisscherG., MesureL., MeurisB., IvanovaA., and FlamengW.Improved endothelialization and reduced thrombosis by coating a synthetic vascular graft with fibronectin and stem cell homing factor SDF-1alpha. Acta Biomater, 8, 1330, 2012.
69.
ThompsonS.A., SmithG.B., CobbS.M., WaltersK.S., and BehrendtD.M.Effects of calcium channel blockers on calcium uptake in rat aortic valve allografts. Circulation, 86, 1973, 1992.
70.
ZhangY., ZhangW., WangK.Q., LiT., SongS.H., and YuanB.Expression of platelet-derived growth factor in the vascular walls of patients with lower extremity arterial occlusive disease. Exp Ther Med, 9, 1223, 2015.
LegareJ.F., RossD.B., IssekutzT.B., RuigrokW., CreaserK., HirschG.M., and LeeT.D.Prevention of allograft heart valve failure in a rat model. J Thorac Cardiovasc Surg, 122, 310, 2001.
73.
TeshimaE., BurghardF., AubinH., AssmannA., BarthM., LichtenbergA., and AkhyariP.PPAR-gamma activation for inhibition of in vivo calcific degeneration of cardiovascular bioprostheses. Presented at the Inaugural Meeting of the Heart Valve Society, Monaco, 2015.
HabashiJ.P., JudgeD.P., HolmT.M., CohnR.D., LoeysB.L., CooperT.K., MyersL., KleinE.C., LiuG., CalviC., PodowskiM., NeptuneE.R., HalushkaM.K., BedjaD., GabrielsonK., RifkinD.B., CartaL., RamirezF., HusoD.L., and DietzH.C.Losartan, an AT1 antagonist, prevents aortic aneurysm in a mouse model of Marfan syndrome. Science, 312, 117, 2006.
76.
LeeS.H., LeeB.W., KimS.W., and ChooS.J.The effects of losartan in preserving the structural integrity of decellularized small diameter vascular allograft conduit implants in vivo. Artif Organs, 41, 98, 2017.
77.
PintoA., ImmohrM.B., JahnA., JenkeA., BoekenU., LichtenbergA., and AkhyariP.The extracellular isoform of superoxide dismutase has a significant impact on cardiovascular ischaemia and reperfusion injury during cardiopulmonary bypass. Eur J Cardiothorac Surg, 50, 1035, 2016.
Supplementary Material
Please find the following supplemental material available below.
For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.
For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.
